Targovax ASA
ONCOLYTIC ADENOVIRAL VECTOR EXPRESSING PEPTIDYLARGININE DEIMINASE AND TISSUE INHIBITOR OF METALLOPROTEINASE
Last updated:
Abstract:
The present invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing peptidylarginine deiminase and TIMP in a cell and increasing anti-tumor effect and induction of specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing transgenes in a cell and increasing anti-tumor effect and generation of specific immune response in a subject.
Utility
16 Apr 2020
19 May 2022